Jul. 16 at 10:02 AM
Citizens reiterated
$RAPP Market Outperform-
$28 after a KOL call reinforced its confidence in the pot'l for positive RAP-219 Phase 2 results in focal epilepsy.
$PRAX $XENE $BHVN $NBIX TAK UCBJY
Citizens said in its note: "We recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy KOL, for a discussion on the upcoming Phase 2 proof-of-concept results for RAP-219 in focal epilepsy. Dr. Rao is optimistic about the potential for RAP-219 in focal epilepsy due to its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design. RAPP remains one of our two high-conviction calls into the Phase 2 results in September."
